Search SEC
Fundamental Analysis
147 matches · 10756 cached companies
| Company | Fundamental | Momentum | Acceleration | Confidence | Revenue Growth | ROIC | FCF Growth | Op Margin Delta | Share Growth | Dividend Yield | Dividend Years | Payout Ratio | P/E | Signals |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 91 | 100 | 100 | 91 | +19.76% | +33.2% | n/a | +90.72% | -2.91% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction, Share count reduction, Strong operating leverage |
| NEPHNEPHROS INC | 86.2 | 87.5 | 92.5 | 91 | +34.56% | +17.86% | n/a | +53.63% | +4.68% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction, Strong operating leverage1 warning |
| ELTPELITE PHARMACEUTICALS INC /NV/ | 84.9 | 100 | 100 | 91 | +107.85% | +73.84% | n/a | +16.82% | +5.65% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction, Strong operating leverage1 warning |
| RLRALPH LAUREN CORP | 81.5 | 75.3 | 85.2 | 91 | +22.08% | +59.4% | n/a | +3.63% | -3.92% | 1.05% | 24 | 23.01% | 21.18x | Gross margin expansion, Operating leverage, ROIC expansion, Share count reduction, Strong operating leverage |
| TBPHTheravance Biopharma, Inc. | 86.6 | 100 | 100 | 85 | +35.11% | n/a | n/a | +101.38% | +1.86% | 0% | 0 | n/a | 16.35x | Operating leverage, Net debt reduction |
| PHRPhreesia, Inc. | 72.8 | 100 | 100 | 100 | +16.88% | +3.7% | +190.98% | +69.04% | +6.01% | 0% | 0 | n/a | n/a | Operating leverage, FCF growth, ROIC expansion, Net debt reduction1 warning |
| APHAmphenol Corporation | 84.4 | 80.8 | 80.8 | 86 | +79.58% | +58.34% | n/a | +6.08% | +1.82% | 0.36% | 22 | 20.14% | 22.25x | Gross margin expansion, Operating leverage, Net debt reduction, Strong operating leverage |
| PHParker-Hannifin Corp | 69.7 | 63.9 | 73.4 | 100 | +3.29% | +29.21% | -8.67% | +3.62% | -2.14% | 0.78% | 42 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction, Share count reduction, Strong operating leverage1 warning |
| ANIPANI PHARMACEUTICALS INC | 83.5 | 93.6 | 96.2 | 83 | +51.82% | +16.93% | n/a | +35.17% | +9.32% | 0% | 0 | 1.48% | 17.7x | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction, Strong operating leverage1 warning |
| PAHCPHIBRO ANIMAL HEALTH CORP | 66.2 | 89.9 | 93.9 | 100 | +57.45% | +15.31% | +217.22% | +3.73% | +0.79% | 1.29% | 13 | 19.68% | 15.45x | Gross margin expansion, Operating leverage, FCF growth, ROIC expansion, Net debt reduction, Strong operating leverage |
| ACADACADIA PHARMACEUTICALS INC | 70.4 | 44 | 44 | 89 | +18.75% | +30.37% | n/a | n/a | +3.09% | 0% | 0 | n/a | 25.82x | Gross margin expansion, Net debt reduction1 warning |
| BDCOBLUE DOLPHIN ENERGY CO | 66.2 | 100 | 100 | 91 | +13.7% | +82.4% | n/a | +12.99% | 0% | 0% | 0 | n/a | 7.24x | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction1 warning |
| AGIOAGIOS PHARMACEUTICALS, INC. | 66.8 | 100 | 86 | 90 | +163.31% | -69.2% | n/a | +5,431.19% | +3.53% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion |
| PLABPHOTRONICS INC | 59.9 | 33.7 | 30 | 100 | +1.21% | +26.35% | -4.86% | -2.08% | -3.7% | 0% | 0 | n/a | 14.65x | Net debt reduction, Share count reduction3 warnings |
| RIGLRIGEL PHARMACEUTICALS INC | 76.4 | 100 | 100 | 77 | +76.37% | +60.89% | n/a | +124.4% | +7.71% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, Net debt reduction, Strong operating leverage2 warnings |
| GOOGAlphabet Inc. | 68.9 | n/a | n/a | 85 | +24.63% | +29.54% | n/a | +2.81% | n/a | 0.25% | 3 | 7.6% | 17.61x | Net debt reduction |
| GOOGLAlphabet Inc. | 68.9 | n/a | n/a | 85 | +24.63% | +29.54% | n/a | +2.81% | n/a | 0.25% | 3 | 7.6% | 17.77x | Net debt reduction |
| GOOGMAlphabet Inc. | 68.9 | n/a | n/a | 85 | +24.63% | +29.54% | n/a | +2.81% | n/a | 1.23% | 1 | 7.6% | 2.53x | Net debt reduction |
| GOOGNAlphabet Inc. | 68.9 | n/a | n/a | 85 | +24.63% | +29.54% | n/a | +2.81% | n/a | 1.23% | 1 | 7.6% | 2.51x | Net debt reduction |
| KNSAKiniksa Pharmaceuticals International, plc | 78.3 | 100 | 100 | 74 | +87.55% | +33.9% | n/a | n/a | +14.89% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction2 warnings |
| VRTXVERTEX PHARMACEUTICALS INC / MA | 63.7 | 100 | 100 | 91 | +13.64% | +33.82% | n/a | -1% | -1.66% | 0% | 0 | n/a | 30.33x | Operating leverage, ROIC expansion, Net debt reduction, Share count reduction |
| ABUSArbutus Biopharma Corp | 62.9 | 100 | 100 | 91 | +2,909.09% | +145.09% | n/a | +272.61% | +3.55% | 0% | 0 | n/a | n/a | Operating leverage, Net debt reduction |
| XERSXeris Biopharma Holdings, Inc. | 69.2 | 100 | 100 | 83 | +58.13% | +12.16% | n/a | +153.29% | +13.37% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction1 warning |
| ETONEton Pharmaceuticals, Inc. | 79.5 | 100 | 100 | 70 | +131.25% | +28.38% | n/a | +201.99% | +21.95% | 0% | 0 | n/a | 210.57x | Operating leverage, Net debt reduction2 warnings |
| AMPHAmphastar Pharmaceuticals, Inc. | 59.8 | 0 | 11.9 | 91 | +0.75% | +16% | n/a | -1.11% | -11.36% | 0% | 0 | n/a | n/a | Net debt reduction, Share count reduction3 warnings |
1-25 of 147